Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates Benefits of Lysine Conjugation.

Yoder NC, Bai C, Tavares D, Widdison WC, Whiteman KR, Wilhelm A, Wilhelm SD, McShea MA, Maloney EK, Ab O, Wang L, Jin S, Erickson HK, Keating TA, Lambert JM.

Mol Pharm. 2019 Jul 9. doi: 10.1021/acs.molpharmaceut.9b00529. [Epub ahead of print]

PMID:
31287952
2.

Alkaloids from the root of Indonesian Annona muricata L.

Nugraha AS, Haritakun R, Lambert JM, Dillon CT, Keller PA.

Nat Prod Res. 2019 Jul 8:1-9. doi: 10.1080/14786419.2019.1638380. [Epub ahead of print]

PMID:
31282747
3.

Effects of Dexmethylphenidate on Targeted and Non-Targeted Behaviours during Functional Analyses: A Brief Report.

Torelli JN, Lambert JM, Francis RN, Picou CG, Mastel MA, O'Flaherty CA, Vandelaar EM.

Dev Neurorehabil. 2019 Jan 11:1-4. doi: 10.1080/17518423.2019.1566279. [Epub ahead of print]

PMID:
30632865
4.

Sphingolipids in adipose tissue: What's tipping the scale?

Lambert JM, Anderson AK, Cowart LA.

Adv Biol Regul. 2018 Dec;70:19-30. doi: 10.1016/j.jbior.2018.10.002. Epub 2018 Oct 15. Review.

PMID:
30473005
5.

Decreasing Food Stealing of Child with Prader-Willi Syndrome Through Function-Based Differential Reinforcement.

Lambert JM, Parikh N, Stankiewicz KC, Houchins-Juarez NJ, Morales VA, Sweeney EM, Milam ME.

J Autism Dev Disord. 2019 Feb;49(2):721-728. doi: 10.1007/s10803-018-3747-y.

PMID:
30229359
6.

Physiological and druggable skipping of immunoglobulin variable exons in plasma cells.

Ashi MO, Srour N, Lambert JM, Marchalot A, Martin O, Le Noir S, Pinaud E, Ayala MV, Sirac C, Saulière J, Moreaux J, Cogné M, Delpy L.

Cell Mol Immunol. 2018 Aug 20. doi: 10.1038/s41423-018-0160-6. [Epub ahead of print]

PMID:
30127381
7.

Behavioral contrast: Research and areas for investigation.

Boyle MA, Hoffmann AN, Lambert JM.

J Appl Behav Anal. 2018 Jul;51(3):702-718. doi: 10.1002/jaba.469. Epub 2018 May 16.

PMID:
29770433
8.

Myristate-induced endoplasmic reticulum stress requires ceramide synthases 5/6 and generation of C14-ceramide in intestinal epithelial cells.

Choi S, Snider JM, Olakkengil N, Lambert JM, Anderson AK, Ross-Evans JS, Cowart LA, Snider AJ.

FASEB J. 2018 Oct;32(10):5724-5736. doi: 10.1096/fj.201800141R. Epub 2018 May 16.

PMID:
29768040
9.

Behavioral Interventions for Inappropriate Sexual Behavior in Individuals With Developmental Disabilities and Acquired Brain Injury: A Review.

Clay CJ, Bloom SE, Lambert JM.

Am J Intellect Dev Disabil. 2018 May;123(3):254-282. doi: 10.1352/1944-7558-123.3.254. Review.

PMID:
29671636
10.

Antibody-Drug Conjugates for Cancer Treatment.

Lambert JM, Berkenblit A.

Annu Rev Med. 2018 Jan 29;69:191-207. doi: 10.1146/annurev-med-061516-121357.

PMID:
29414262
11.

Teacher-Conducted, Latency-Based Functional Analysis as Basis for Individualized Levels System in a Classroom Setting.

Lambert JM, Lopano SE, Noel CR, Ritchie MN.

Behav Anal Pract. 2017 Sep 6;10(4):422-426. doi: 10.1007/s40617-017-0200-1. eCollection 2017 Dec.

12.

Individualized Levels System and Systematic Stimulus Pairing to Reduce Multiply Controlled Aggression of a Child With Autism Spectrum Disorder.

Randall KR, Lambert JM, Matthews MP, Houchins-Juarez NJ.

Behav Modif. 2018 May;42(3):422-440. doi: 10.1177/0145445517741473. Epub 2017 Nov 22.

PMID:
29166775
13.

Outcome summaries of latency-based functional analyses conducted in hospital inpatient units.

Lambert JM, Staubitz JE, Roane JT, Houchins-Juárez NJ, Juárez AP, Sanders KB, Warren ZE.

J Appl Behav Anal. 2017 Jul;50(3):487-494. doi: 10.1002/jaba.399. Epub 2017 May 29.

PMID:
28556903
14.

Mutant p53 targeting by the low molecular weight compound STIMA-1.

Zache N, Lambert JMR, Rökaeus N, Shen J, Hainaut P, Bergman J, Wiman KG, Bykov VJN.

Mol Oncol. 2017 May;11(5):595. doi: 10.1002/1878-0261.12065. No abstract available.

15.

Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.

Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, Wang L, Dong L, Setiady Y, Maloney EK, Ab O, Zhang X, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM.

Bioconjug Chem. 2017 May 17;28(5):1371-1381. doi: 10.1021/acs.bioconjchem.7b00062. Epub 2017 Apr 13.

PMID:
28388844
16.

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Lambert JM, Morris CQ.

Adv Ther. 2017 May;34(5):1015-1035. doi: 10.1007/s12325-017-0519-6. Epub 2017 Mar 30. Review.

17.

Brief Report: Clustered Forward Chaining with Embedded Mastery Probes to Teach Recipe Following.

Chazin KT, Bartelmay DN, Lambert JM, Houchins-Juárez NJ.

J Autism Dev Disord. 2017 Apr;47(4):1249-1255. doi: 10.1007/s10803-017-3038-z.

PMID:
28144879
18.

Chaining Functional Basketball Sequences (with Embedded Conditional Discriminations) in an Adolescent with Autism.

Lambert JM, Copeland BA, Karp EL, Finley CI, Houchins-Juarez NJ, Ledford JR.

Behav Anal Pract. 2016 Apr 28;9(3):199-210. doi: 10.1007/s40617-016-0125-0. eCollection 2016 Sep.

19.

Assessing Acquisition of and Preference for Mand Topographies During Functional Communication Training.

Torelli JN, Lambert JM, Da Fonte MA, Denham KN, Jedrzynski TM, Houchins-Juarez NJ.

Behav Anal Pract. 2015 Aug 18;9(2):165-8. doi: 10.1007/s40617-015-0083-y. eCollection 2016 Jun.

20.

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV.

Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23.

21.

A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.

Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, Fishkin N, Dong L, Jones GE, Coccia JA, Lanieri L, Veale K, Costoplus JA, Skaletskaya A, Gabriel R, Salomon P, Wu R, Qiu Q, Erickson HK, Lambert JM, Chari RV, Widdison WC.

Mol Cancer Ther. 2016 Jun;15(6):1311-20. doi: 10.1158/1535-7163.MCT-16-0021. Epub 2016 Mar 29.

22.

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.

Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, Lanieri L, Bogalhas M, Wang L, Wilhelm S, Widdison W, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM.

Bioconjug Chem. 2016 Jul 20;27(7):1588-98. doi: 10.1021/acs.bioconjchem.6b00117. Epub 2016 Jun 20.

PMID:
27174129
23.

Antibody-drug conjugates: targeted delivery and future prospects.

Lambert JM.

Ther Deliv. 2016;7(5):279-82. doi: 10.4155/tde-2016-0010. No abstract available.

24.

New developments for antibody-drug conjugate-based therapeutic approaches.

de Goeij BE, Lambert JM.

Curr Opin Immunol. 2016 Jun;40:14-23. doi: 10.1016/j.coi.2016.02.008. Epub 2016 Mar 7. Review.

25.

The INNs and outs of antibody nonproprietary names.

Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.

MAbs. 2016;8(1):1-9. doi: 10.1080/19420862.2015.1114320.

26.

Implications for practice: Resurgence and differential reinforcement of alternative responding.

Bloom SE, Lambert JM.

J Appl Behav Anal. 2015 Dec;48(4):781-4. doi: 10.1002/jaba.266. Epub 2015 Oct 19.

PMID:
26477525
27.

Serial alternative response training as intervention for target response resurgence.

Lambert JM, Bloom SE, Samaha AL, Dayton E, Rodewald AM.

J Appl Behav Anal. 2015 Dec;48(4):765-80. doi: 10.1002/jaba.253. Epub 2015 Sep 24.

PMID:
26404022
28.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.

Gohil SH, Ardeshna KM, Lambert JM, Pule MA, Mohamedbhai S, Virchis A, Morris EC, Linch DC, Thomson KJ, Peggs KS.

Br J Haematol. 2015 Oct;171(2):197-204. doi: 10.1111/bjh.13561. Epub 2015 Jun 26.

PMID:
26119524
29.

Antibody-Drug Conjugates (ADCs): Magic Bullets at Last!

Lambert JM.

Mol Pharm. 2015 Jun 1;12(6):1701-2. doi: 10.1021/acs.molpharmaceut.5b00302. No abstract available.

PMID:
26027696
30.

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.

Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.

31.

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.

Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, Blanc V, Lambert JM.

Mol Pharm. 2015 Jun 1;12(6):1703-16. doi: 10.1021/acs.molpharmaceut.5b00175. Epub 2015 Apr 27.

PMID:
25856201
32.

Latency-Based FA as Baseline for Subsequent Treatment Evaluation.

Caruthers CE, Lambert JM, Chazin KM, Harbin ER, Houchins-Juarez NJ.

Behav Anal Pract. 2015 Mar 26;8(1):48-51. eCollection 2015 May.

33.

Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.

Lai KC, Deckert J, Setiady YY, Shah P, Wang L, Chari R, Lambert JM.

Pharm Res. 2015 Nov;32(11):3593-603. doi: 10.1007/s11095-015-1633-2. Epub 2015 Jan 29.

PMID:
25630819
34.

Dissecting post-mating prezygotic speciation phenotypes.

Shaw KL, Lambert JM.

Bioessays. 2014 Nov;36(11):1050-3. doi: 10.1002/bies.201400096. Epub 2014 Aug 29.

PMID:
25171419
35.

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

Lambert JM, Chari RV.

J Med Chem. 2014 Aug 28;57(16):6949-64. doi: 10.1021/jm500766w. Epub 2014 Jul 10.

PMID:
24967516
36.

Training residential staff and supervisors to conduct traditional functional analyses.

Lambert JM, Bloom SE, Clay CJ, Kunnavatana SS, Collins SD.

Res Dev Disabil. 2014 Jul;35(7):1757-65. doi: 10.1016/j.ridd.2014.02.014. Epub 2014 Mar 20.

PMID:
24656603
37.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.

MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.

38.

Fusobacterium liver abscess.

Buelow BD, Lambert JM, Gill RM.

Case Rep Gastroenterol. 2013 Nov 12;7(3):482-6. doi: 10.1159/000356821. eCollection 2013.

39.

Evaluation of some components of choice making.

Sellers TP, Bloom SE, Samaha AL, Dayton E, Lambert JM, Keyl-Austin AA.

J Appl Behav Anal. 2013 Summer;46(2):455-64. doi: 10.1002/jaba.46. Epub 2013 May 20.

PMID:
24114160
40.

Training residential staff to conduct trial-based functional analyses.

Lambert JM, Bloom SE, Kunnavatana SS, Collins SD, Clay CJ.

J Appl Behav Anal. 2013 Spring;46(1):296-300. doi: 10.1002/jaba.17. Epub 2013 Feb 20.

PMID:
24114102
41.

Teacher-conducted trial-based functional analyses as the basis for intervention.

Bloom SE, Lambert JM, Dayton E, Samaha AL.

J Appl Behav Anal. 2013 Spring;46(1):208-18. doi: 10.1002/jaba.21.

PMID:
24114095
42.

The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain.

Breivogel CS, Puri V, Lambert JM, Hill DK, Huffman JW, Razdan RK.

J Recept Signal Transduct Res. 2013 Dec;33(6):367-79. doi: 10.3109/10799893.2013.838787. Epub 2013 Oct 4.

PMID:
24094141
43.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J, Lutz RJ, Chittenden T, Lambert JM.

Blood. 2013 Nov 14;122(20):3500-10. doi: 10.1182/blood-2013-05-505685. Epub 2013 Sep 3.

44.

Drug-conjugated antibodies for the treatment of cancer.

Lambert JM.

Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review.

45.

Trial-based functional analysis and functional communication training in an early childhood setting.

Lambert JM, Bloom SE, Irvin J.

J Appl Behav Anal. 2012 Fall;45(3):579-84. doi: 10.1901/jaba.2012.45-579.

46.

ADME of antibody-maytansinoid conjugates.

Erickson HK, Lambert JM.

AAPS J. 2012 Dec;14(4):799-805. doi: 10.1208/s12248-012-9386-x. Epub 2012 Aug 9. Review.

47.

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI.

J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2.

48.

Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.

Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, Chari RV.

J Med Chem. 2012 Jan 26;55(2):766-82. doi: 10.1021/jm201284m. Epub 2012 Jan 5.

PMID:
22148292
49.

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.

Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Review.

50.

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP.

Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26.

PMID:
21519855

Supplemental Content

Loading ...
Support Center